Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate. GCPII expression is considerably increased in prostate carcinoma, and the enzyme also participates in glutamate excitotoxicity in the brain. Therefore, GCPII represents an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity. For the development of novel therapeutics, mouse models are widely used. However, although mouse GCPII activity has been characterized, a detailed comparison of the enzymatic activity and tissue distribution of the mouse and human GCPII orthologs remains lacking. In this study, we prepared extracellular mouse GCPII and compared it with human GCPII. We found that mouse GCPII possesses lower catalytic efficiency but similar substrate specificity compared with the human protein. Using a panel of GCPII inhibitors, we discovered that inhibition constants are generally similar for mouse and human GCPII. Furthermore, we observed highest expression of GCPII protein in the mouse kidney, brain, and salivary glands. Importantly, we did not detect GCPII in the mouse prostate. Our data suggest that the differences in enzymatic activity and inhibition profile are rather small; therefore, mouse GCPII can approximate human GCPII in drug development and testing. On the other hand, significant differences in GCPII tissue expression must be taken into account when developing novel GCPII-based anticancer and therapeutic methods, including targeted anticancer drug delivery systems, and when using mice as a model organism.

1st Faculty of Medicine Charles University Prague Czech Republic

Department of Biochemistry Faculty of Science Charles University Prague Czech Republic

Department of Genetics and Microbiology Faculty of Science Charles University Prague Czech Republic

Department of Normal Pathological and Clinical Physiology 3rd Faculty of Medicine Charles University Prague Czech Republic

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic

Present address Donnelly Centre for Cellular and Biomolecular Research University of Toronto Toronto ON Canada

Zobrazit více v PubMed

Berger UV, Carter RE, Mckee M and Coyle JT (1995) N‐acetylated alpha‐linked acidic dipeptidase is expressed by non‐myelinating Schwann‐cells in the peripheral nervous‐system. J Neurocytol 24, 99–109. PubMed

Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T and Konvalinka J (2007) Expression of glutamate carboxypeptidase II in human brain. Neuroscience 144, 1361–1372. PubMed

Bostwick DG, Pacelli A, Blute M, Roche P and Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82, 2256–2261. PubMed

Silver DA, Pellicer I, Fair WR, Heston WD and Cordon‐Cardo C (1997) Prostate‐specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3, 81–85. PubMed

Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin SL, Tong WP, May F, Mukherjee B and Heston WDW (1996) Prostate‐specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2, 1445–1451. PubMed

Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY and Haas GP (2006) Expression of prostate‐specific membrane antigen in normal and malignant human tissues. World J Surg 30, 628–636. PubMed

Robinson MB, Blakely RD, Couto R and Coyle JT (1987) Hydrolysis of the brain dipeptide N‐acetyl‐L‐aspartyl‐L‐glutamate. Identification and characterization of a novel N‐acetylated alpha‐linked acidic dipeptidase activity from rat brain. J Biol Chem 262, 14498–14506. PubMed

Horoszewicz JS, Kawinski E and Murphy GP (1987) Monoclonal‐antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic‐cancer patients. Anticancer Res 7, 927–936. PubMed

Bacich DJ, Ramadan E, O'Keefe DS, Bukhari N, Wegorzewska I, Ojeifo O, Olszewski R, Wrenn CC, Bzdega T, Wroblewska B et al (2002) Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N‐acetylaspartylglutamate. J Neurochem 83, 20–29. PubMed

Hlouchova K, Barinka C, Klusak V, Sacha P, Mlcochova P, Majer P, Rulisek L and Konvalinka J (2007) Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem 101, 682–696. PubMed

Collard F, Vertommen D, Constantinescu S, Buts L and Van Schaftingen E (2011) Molecular identification of beta‐citrylglutamate hydrolase as glutamate carboxypeptidase 3. J Biol Chem 286, 38220–38230. PubMed PMC

Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XCM et al (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 5, 1396–1402. PubMed

Neale JH, Olszewski RT, Gehl LM, Wroblewska B and Bzdega T (2005) The neurotransmitter N‐acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci 26, 477–484. PubMed

Wroblewska B, Wroblewski JT, Pshenichkin S, Surin A, Sullivan SE and Neale JH (1997) N‐acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 69, 174–181. PubMed

Bruno V, Wroblewska B, Wroblewski JT, Fiore L and Nicoletti F (1998) Neuroprotective activity of N‐acetylaspartylglutamate in cultured cortical cells. Neuroscience 85, 751–757. PubMed

Halsted CH, Ling EH, Luthi‐Carter R, Villanueva JA, Gardner JM and Coyle JT (1998) Folylpoly‐gamma‐glutamate carboxypeptidase from pig jejunum – molecular characterization and relation to glutamate carboxypeptidase II. J Biol Chem 273, 20417–20424. PubMed

Chandler CJ, Wang TT and Halsted CH (1986) Pteroylpolyglutamate hydrolase from human jejunal brush borders. Purification and characterization. J Biol Chem 261, 928–933. PubMed

Mhawech‐Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR and Penetrante R (2007) Prostate‐specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology 50, 472–483. PubMed

Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee SR, Winnard PT Jr, Artemov D, Glunde K, Pomper MG and Bhujwalla ZM (2012) PSMA‐targeted theranostic nanoplex for prostate cancer therapy. ACS Nano 6, 7752–7762. PubMed PMC

Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ et al (2016) Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol 196, 382–391. PubMed

Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A et al (2012) Preclinical development and clinical translation of a PSMA‐targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4, 128ra39. PubMed

Rovenska M, Hlouchova K, Sacha P, Mlochova P, Horak V, Zamecnik J, Barinka C and Konvalinka J (2008) Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate 68, 171–182. PubMed

Zhong C, Zhao X, Van KC, Bzdega T, Smyth A, Zhou J, Kozikowski AP, Jiang J, O'Connor WT, Berman RF et al (2006) NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J Neurochem 97, 1015–1025. PubMed

Zhong CL, Zhao XR, Sarva J, Kozikowski A, Neale JH and Lyeth BG (2005) NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J Neurotraum 22, 266–276. PubMed

Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ et al (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA 100, 9554–9559. PubMed PMC

Chen SR, Wozniak KM, Slusher BS and Pan HL (2002) Effect of 2‐(phosphono‐methyl)‐pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther 300, 662–667. PubMed

Nagel J, Belozertseva I, Greco S, Kashkin V, Malyshkin A, Jirgensons A, Shekunova E, Eilbacher B, Bespalov A and Danysz W (2006) Effects of NAAG peptidase inhibitor 2‐PMPA in model chronic pain – relation to brain concentration. Neuropharmacology 51, 1163–1171. PubMed

Zhou J, Neale JH, Pomper MG and Kozikowski AP (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 4, 1015–1026. PubMed

Bacich DJ, Pinto JT, Tong WP and Heston WD (2001) Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate‐specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 12, 117–123. PubMed

Gao Y, Xu SY, Cui ZW, Zhang MK, Lin YY, Cai L, Wang ZG, Luo XG, Zheng Y, Wang Y et al (2015) Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury. J Neurochem 134, 340–353. PubMed

Tsai G, Dunham KS, Drager U, Grier A, Anderson C, Collura J and Coyle JT (2003) Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants. Synapse 50, 285–292. PubMed

Han LQ, Picker JD, Schaevitz LR, Tsai GC, Feng JM, Jiang ZC, Chu HC, Basu AC, Berger‐Sweeney J and Coyle JT (2009) Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse 63, 625–635. PubMed PMC

Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS and Konvalinka J (2002) Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 80, 477–487. PubMed

Tykvart J, Sacha P, Barinka C, Knedlik T, Starkova J, Lubkowski J and Konvalinka J (2012) Efficient and versatile one‐step affinity purification of in vivo biotinylated proteins: expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II. Protein Expr Purif 82, 106–115. PubMed PMC

Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA and Trainor DA (1996) Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N‐acetylated alpha‐linked acidic dipeptidase. J Med Chem 39, 619–622. PubMed

Kozikowski AP, Zhang J, Nan FJ, Petukhov PA, Grajkowska E, Wroblewski JT, Yamamoto T, Bzdega T, Wroblewska B and Neale JH (2004) Synthesis of urea‐based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 47, 1729–1738. PubMed

Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambahatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC et al (2008) Radiohalogenated prostate‐specific membrane antigen (PSMA)‐based ureas as imaging agents for prostate cancer. J Med Chem 51, 7933–7943. PubMed PMC

Eder M, Schafer M, Bauder‐Wust U, Hull WE, Wangler C, Mier W, Haberkorn U and Eisenhut M (2012) Ga‐68‐complex lipophilicity and the targeting property of a urea‐based PSMA inhibitor for PET imaging. Bioconjug Chem 23, 688–697. PubMed

Tykvart J, Schimer J, Barinkova J, Pachl P, Postova‐Slavetinska L, Majer P, Konvalinka J and Sacha P (2014) Rational design of urea‐based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery. Bioorg Med Chem 22, 4099–4108. PubMed

Tykvart J, Schimer J, Jancarik A, Barinkova J, Navratil V, Starkova J, Sramkova K, Konvalinka J, Majer P and Sacha P (2015) Design of highly potent urea‐based, exosite‐binding inhibitors selective for glutamate carboxypeptidase II. J Med Chem 58, 4357–4363. PubMed

Tykvart J, Barinka C, Svoboda M, Navratil V, Soucek R, Hubalek M, Hradilek M, Sacha P, Lubkowski J and Konvalinka J (2015) Structural and biochemical characterization of a novel aminopeptidase from human intestine. J Biol Chem 290, 11321–11336. PubMed PMC

Tykvart J, Navratil V, Sedlak F, Corey E, Colombatti M, Fracasso G, Koukolik F, Barinka C, Sacha P and Konvalinka J (2014) Comparative analysis of monoclonal antibodies against prostate‐specific membrane antigen (PSMA). Prostate 74, 1674–1690. PubMed

Navratil M, Tykvart J, Schimer J, Pachl P, Navratil V, Rokob TA, Hlouchova K, Rulisek L and Konvalinka J (2016) Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities. FEBS J 283, 2528–2545. PubMed

Majer P, Jancarik A, Krecmerova M, Tichy T, Tenora L, Wozniak K, Wu Y, Pommier E, Ferraris D, Rais R et al (2016) Discovery of orally available prodrugs of the glutamate carboxypeptidase II (GCPII) inhibitor 2‐phosphonomethylpentanedioic acid (2‐PMPA). J Med Chem 59, 2810–2819. PubMed

Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC and Pomper MG (2009) A low molecular weight PSMA‐based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 390, 624–629. PubMed PMC

Gorin MA, Pomper MG and Rowe SP (2016) PSMA‐targeted imaging of prostate cancer: the best is yet to come. BJU Int 117, 715–716. PubMed

Yang X, Mease RC, Pullambhatla M, Lisok A, Chen Y, Foss CA, Wang Y, Shallal H, Edelman H, Hoye AT et al (2016) [(18)F]Fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate‐specific membrane antigen (PSMA). J Med Chem 59, 206–218. PubMed PMC

Barinka C, Hlouchova K, Rovenska M, Majer P, Dauter M, Hin N, Ko YS, Tsukamoto T, Slusher BS, Konvalinka J et al (2008) Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J Mol Biol 376, 1438–1450. PubMed PMC

Barinka C, Rovenska M, Mlcochova P, Hlouchova K, Plechanovova A, Majer P, Tsukamoto T, Slusher BS, Konvalinka J and Lubkowski J (2007) Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem 50, 3267–3273. PubMed

Mlcochova P, Plechanovova A, Barinka C, Mahadevan D, Saldanha JW, Rulisek L and Konvalinka J (2007) Mapping of the active site of glutamate carboxypeptidase II by site‐directed mutagenesis. FEBS J 274, 4731–4741. PubMed

O'Keefe DS, Bacich DJ and Heston WD (2004) Comparative analysis of prostate‐specific membrane antigen (PSMA) versus a prostate‐specific membrane antigen‐like gene. Prostate 58, 200–210. PubMed

Shafizadeh TB and Halsted CH (2007) Gamma‐glutamyl hydrolase, not glutamate carboxypeptidase II, hydrolyzes dietary folate in rat small intestine. J Nutr 137, 1149–1153. PubMed

Knedlik T, Navratil V, Vik V, Pacik D, Sacha P and Konvalinka J (2014) Detection and quantitation of glutamate carboxypeptidase II in human blood. Prostate 74, 768–780. PubMed

Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH and Rajasekaran AK (2003) A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate‐specific membrane antigen. Mol Biol Cell 14, 4835–4845. PubMed PMC

Klusak V, Barinka C, Plechanovova A, Mlcochova P, Konvalinka J, Rulisek L and Lubkowski J (2009) Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X‐ray crystallography, and computational methods. Biochemistry 48, 4126–4138. PubMed PMC

Mesters JR, Barinka C, Li WX, Tsukamoto T, Majer P, Slusher BS, Konvalinka J and Hilgenfeld R (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 25, 1375–1384. PubMed PMC

Speno HS, Luthi‐Carter R, Macias WL, Valentine SL, Joshi ART and Coyle JT (1999) Site‐directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol 55, 179–185. PubMed

Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer